文献速递冠心病心力衰竭与心肌病

STEMI合并多支血管病变及心力衰竭患者完全血运重建时机的OPTION-STEMI试验

Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.
PubMed 文献 · Eur Heart J · 2026-01-01

OPTION-STEMI试验比较了ST段抬高型心肌梗死(STEMI)合并多支血管病变患者入院期间行即刻或分阶段完全血运重建的效果,主要终点为1年全因死亡、非致死性心肌梗死或非计划血运重建的复合终点。结果显示,即刻完全血运重建未达非劣效性。按入院时心力衰竭(Killip II或III级)进行亚组分析,发现心力衰竭患者中即刻策略的主要终点发生率高于分阶段策略,而无心力衰竭患者中两种策略无显著差异。

要点

  • 心力衰竭患者(Killip II-III)中,即刻完全血运重建1年主要终点高于分阶段策略(22.8% vs 13.3%,HR 1.79,95%CI 1.05-3.04)。

核心结论

  • 在OPTION-STEMI试验中,非心源性休克的STEMI合并多支病变患者,即刻完全血运重建相比分阶段策略未达到非劣效性,但更差结局可能仅限于入院时有心力衰竭的患者。

研究设计与样本

  • 前瞻性随机对照试验,比较即刻与分阶段完全血运重建策略。
  • 共994名随机患者,其中329名(33.1%)入院时有心力衰竭(Killip II或III级)。
  • 主要终点为1年全因死亡、非致死性心肌梗死或非计划血运重建的复合终点。

主要发现

  • 心力衰竭患者中,即刻组主要终点高于分阶段组(22.8% vs 13.3%;HR 1.79;95%CI 1.05-3.04)。

关键数值与推荐

  • 心力衰竭定义为入院时Killip分级II或III级。
  • 主要终点为死亡、非致死性心肌梗死或非计划血运重建的复合终点,随访1年。
  • 即刻完全血运重建未达非劣效性(原文未提供非劣效界值)。

临床怎么用

  • 在STEMI合并多支血管病变且入院时存在心力衰竭(Killip II或III级)的患者中,分阶段完全血运重建可能优于即刻策略。
  • 无心力衰竭的患者中,两种策略的临床结局无显著差异,但即刻策略的非劣效性仍需进一步研究确认。

局限性

  • 亚组分析为预设但样本量有限,需谨慎解读。
  • 试验排除了心源性休克患者,结果不适用于该群体。
  • 未提供非劣效界值及更多细节,非劣效性结论尚不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The optimal timing of complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease complicated by heart failure remains uncertain. METHODS: The OPTION-STEMI (Optimal Timing of Fractional Flow Reserve-Guided Complete Revascularization for Non-Infarct-Related Artery in ST-segment Elevation Myocardial Infarction with Multivessel Disease) trial compared immediate vs staged complete revascularization during the index admission in patients with STEMI and multivessel disease. In the OPTION-STEMI trial, immediate complete revascularization was not found to be non-inferior for the primary endpoint compared with staged complete revascularization. Pre-specified subgroup analysis was performed according to heart failure at admission, defined as Killip class II or III. The primary endpoint was a composite of death from any cause, non-fatal myocardial infarction, or any unplanned revascularization at 1 year. RESULTS: Among 994 randomized patients, 329 (33.1%) had heart failure at admission. These patients had a higher risk of primary endpoint than those without heart failure (18.2% vs 8.7%; adjusted HR 1.63; 95% CI 1.11-2.40; P = .013). At 1 year, immediate complete revascularization was associated with a higher incidence of the primary endpoint than staged complete revascularization in patients with heart failure (22.8% vs 13.3%; HR 1.79; 95% CI 1.05-3.04), but not in those without heart failure (8.0% vs 9.5%; HR 0.84; 95% CI .50-1.40). A significant interaction was observed between heart failure status and randomized strategy (P = .043). CONCLUSIONS: In the OPTION-STEMI trial, among patients with STEMI and multi-vessel disease who were not in cardiogenic shock, immediate complete revascularization was not non-inferior compared with staged complete revascularization. However, subgroup analysis suggests that the worse outcomes with immediate complete revascularization may be limited to patients with heart failure at admission. Further studies are required to demonstrate the non-inferiority of immediate complete revascularization compared with staged complete revascularization in patients without heart failure.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kim, Ahn, Hyun, et al. Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial. Eur Heart J. 2026. PMID: 41493330. doi:10.1093/eurheartj/ehaf924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。